|
|
|
|
Direct Cost |
Indirect Cost |
|
1DP2DA040254-01 |
Engineering Humoral Immunity to Functionally Cure HIV Infection |
MASSACHUSETTS GENERAL HOSPITAL |
NIDA |
$1,500,000 |
$1,110,000 |
$2,610,000 |
1DP5OD021353-01 |
THE MECHANISM OF TSLP ANTI-TUMOR EFFECTS IN THE SKIN |
MASSACHUSETTS GENERAL HOSPITAL |
OD |
$250,000 |
$131,250 |
$381,250 |
1F31DK107187-01 |
Role of the mitochondrial calcium uniporter in brown fat physiology |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$33,646 |
|
$33,646 |
1F32CA192531-01 |
Digital Precision Micro NMR Biosensor for Cancer |
MASSACHUSETTS GENERAL HOSPITAL |
NCI |
$55,190 |
|
$55,190 |
1F32CA192779-01A1 |
Unveiling the mechanism for Spartan-mediated DNA lesion bypass and the implications for breast cancer treatment |
MASSACHUSETTS GENERAL HOSPITAL |
NCI |
$54,194 |
|
$54,194 |
1F32DK102323-01A1 |
Impact of genetic variants on sleep timing and type 2 diabetes risk |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$56,042 |
|
$56,042 |
1F32DK107140-01 |
FGF Signaling in Zebrafish Mesonephric Kidney Regeneration |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$57,962 |
|
$57,962 |
1F32DK107197-01A1 |
Tricyclic Antidepressants Induce Hepatic Stellate Cell Quiescence: Identification of Mechanisms to Halt Hepatic Fibrosis |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$62,066 |
|
$62,066 |
1F32GM114905-01 |
Functional characterization of a mitochondrial orphan enzyme |
MASSACHUSETTS GENERAL HOSPITAL |
NIGMS |
$54,194 |
|
$54,194 |
1F32GM115208-01 |
The Human Knockout Project: systematic discovery of loss-of-function variants in humans |
MASSACHUSETTS GENERAL HOSPITAL |
NIGMS |
$52,406 |
|
$52,406 |
1F32HL128026-01 |
Hyperinflation and Cardiac Impairment in COPD |
MASSACHUSETTS GENERAL HOSPITAL |
NHLBI |
$64,226 |
|
$64,226 |
1F32HL129789-01 |
Assessing Disease Activity in IPF with Novel Biomarkers and Molecular Imaging |
MASSACHUSETTS GENERAL HOSPITAL |
NHLBI |
$64,226 |
|
$64,226 |
1F32MH107091-01 |
Neural language processing and schizophrenia: Bridging perception and interpretation |
MASSACHUSETTS GENERAL HOSPITAL |
NIMH |
$0 |
|
|
1F32NS093769-01 |
Developing a novel cortical-to-spinal neural prosthesis for reconstituting volitional movement of a paralyzed limb |
MASSACHUSETTS GENERAL HOSPITAL |
NINDS |
$64,226 |
|
$64,226 |
1K01AG050711-01 |
Tau Quantitation in AD with High Resolution MRI and PET |
MASSACHUSETTS GENERAL HOSPITAL |
NIA |
$120,502 |
$8,950 |
$129,452 |
1K01DK101628-01A1 |
Novel Features of Integrin Antagonism Applied to Renal Dysfunction |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$148,789 |
$11,903 |
$160,692 |
1K01DK101631-01A1 |
Computational Tools for the Analysis of MRI Images in Type-1 Diabetes |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$148,789 |
$11,903 |
$160,692 |
1K01DK103947-01 |
Gastrointestinal Weight Loss Surgery Regulates Glucose Metabolism via Intestinal Metabolic Remodeling |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$148,300 |
$11,864 |
$160,164 |
1K01DK107836-01 |
Integrating diabetes pathophysiology from genotype to phenotype in whole genome sequence association studies of glycemic traits |
MASSACHUSETTS GENERAL HOSPITAL |
NIDDK |
$143,091 |
$10,540 |
$153,631 |
1K01ES026835-01 |
New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis |
MASSACHUSETTS GENERAL HOSPITAL |
NIEHS |
$214,080 |
$16,726 |
$230,806 |